Cargando…
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
BACKGROUND: The SARS-CoV-2 omicron (B.1.1.529) variant, which was first identified in November, 2021, spread rapidly in many countries, with a spike protein highly diverged from previously known variants, and raised concerns that this variant might evade neutralising antibody responses. We therefore...
Autores principales: | Sheward, Daniel J, Kim, Changil, Ehling, Roy A, Pankow, Alec, Castro Dopico, Xaquin, Dyrdak, Robert, Martin, Darren P, Reddy, Sai T, Dillner, Joakim, Karlsson Hedestam, Gunilla B, Albert, Jan, Murrell, Ben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930016/ https://www.ncbi.nlm.nih.gov/pubmed/35305699 http://dx.doi.org/10.1016/S1473-3099(22)00129-3 |
Ejemplares similares
-
Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022) -
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022) -
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022) -
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
por: Sheward, Daniel J., et al.
Publicado: (2021) -
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)